The fatal attraction between pro-prion and filamin A: Prion as a marker in human cancers

Biomarkers in Medicine

Volumn 4, Issue 3, 2010, Pages 453-464

  Sy, Man Sun ^a   Li, Chaoyang ^a   Yu, Shuiliang ^a   Xin, Wei ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Creutzfeldt Jakob disease; Cytoskeleton; Filamin A; Glycosylphosphatidylinositol anchor; Pancreatic ductal cell adenocarcinoma; Peptide signal sequence; Pre pro prion; Prion; Pro prion; Signal transduction; Transmissible spongiform encephalopathy

Indexed keywords

CELL SURFACE RECEPTOR; FILAMIN A; GLYCOSYLPHOSPHATIDYLINOSITOL; PRION PROTEIN; PROTEIN PRECURSOR; SIGNAL PEPTIDE;

CANCER CELL; CANCER DIAGNOSIS; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; CELL MEMBRANE; CELL MIGRATION; CREUTZFELDT JAKOB DISEASE; DISEASE COURSE; DNA PROTEIN COMPLEX; DRUG TARGETING; EARLY DIAGNOSIS; HUMAN; LIVER CELL CARCINOMA; MELANOMA; OVERALL SURVIVAL; PANCREAS CANCER; PANCREAS DUCT; PANCREATIC DUCTAL CELL ADENOCARCINOMA; PEPTIDE SYNTHESIS; PRION DISEASE; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

CELL LINE, TUMOR; CONTRACTILE PROTEINS; CYTOSKELETON; DIMERIZATION; HUMANS; MELANOMA; MICROFILAMENT PROTEINS; PANCREATIC NEOPLASMS; PRIONS; PROTEIN PRECURSORS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 77953747094     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/bmm.10.14     Document Type: Review

References (110)

1. Asher DM, Gibbs CJ Jr, Gajdusek DC et al.: Pathogenesis of subacute spongiform encephalopathies. Ann. Clin. Lab. Sci. 6(1), 84-103 (1976).
2. Greig JR: Scrapie in Sheep. J. Comp. Pathol. 60(4), 263-266 (1950).
3. Griffith JS: Self-replication and scrapie. Nature 215, 1043-1044 (1967).
4. Prusiner SB: Novel proteinaceous infectious particles cause scrapie. Science 216, 136-144 (1982).
5. Bolton DC, McKinley MP, Prusiner SB: Identification of a protein that purifies with the scrapie prion. Science 218, 1309-1311 (1982).
6. Prusiner SB, Groth DF, Bolton DC, Kent SB, Hood LE: Purification and structural studies of a major scrapie prion protein. Cell 38, 127-134 (1984).
7. Oesch B, Westaway D, Wälchli M et al.: A cellular gene encodes scrapie PrP 27-30 protein. Cell 40, 735-746 (1985).
8. Prusiner SB: Prions. Proc. Natl Acad. Sci. USA 9, 13363-13383 (1998).
9. Smith PG, Cousens SN, d'Huillard Aignaux JN, Ward HJ, Will RG: The epidemiology of variant Creutzfeldt-Jakob disease. Curr. Top Microbiol. Immunol. 284, 161-191 (2004).
10. Brockes JP: Topics in prion cell biology. Curr. Opin. Neurobiol. 9, 571-577 (1999).
11. Harris DA: Cellular biology of prion diseases. Clin. Microbiol. Rev. 12, 429-444 (1999).
12. Donne DG, Viles JH, Groth D et al.: Structure of the recombinant full-length hamster prion protein PrP(29-231): the N-terminus is highly flexible. Proc. Natl Acad. Sci. USA 94, 13452-13457 (1997).
13. Zahn R, Liu A, Lührs T et al.: NMR solution structure of the human prion protein. Proc. Natl Acad. Sci. USA 97, 145-150 (2000). (Pubitemid 30055798)
14. Hegde RS, Rane NS: Prion protein trafficking and the development of neurodegeneration. Trends Neurosci. 26, 337-339 (2003).
15. Behrens A, Aguzzi A: Small is not beautiful: anatogonizing functions for the prion protein PrPc and its homologue Dpl. Trends Neurosci. 25(3), 150-154 (2002).
16. Caughey B, Braon GS: Prions and their partners in crime. Nature 443, 803-810 (2006).
17. Chiesa R, Harris DA: Fishing for prion protein function. PLoS Biol. 7(3), e75 (2009).
18. Caughey B, Brown K, Raymond GJ, Katzenstein GE, Thresher W: Binding of the protease sensitive form of PrP to sulfated glycosaminoglycans and Congo red. J. Virol. 68, 4107-4111 (1994).
19. Pan T, Wong BS, Liu T, Li R, Petersen RB, Sy MS: Cell-surface PrP interacts with glycosaminoglycans. Biochem. J. 368, 81-90 (2002).
20. Rieger R, Edenhofer F, Lasmézas CI, Weiss S: The human 37-kDa laminin receptor precursor interacts with the prion protein in eukaryotic cells. Nat. Med. 3(12), 1383-1388 (1997).
21. Li C, Wong P, Pan T et al.: Normal cellular prion protein is a ligand of selectins: binding requires LeX but is inhibited by sLeX. Biochem. J. 406, 333-341 (2007).
22. Schmitt-Ulms G, Legname G, Baldwin MA et al.: Binding of neural cell adhesion molecules (N-CAMs) to the cellular prion protein. J. Mol. Biol. 314(5), 1209-1225 (2001).
23. Morel E, Fouquet S, Strup-Perrot C et al.: The cellular prion protein PrP is involved in the proliferation of epithelial cells and in the distribution of junction-associated proteins. PLoS ONE 3, e3000 (2008).
24. Brown DR, Qin K, Herms JW et al.: The cellular prion protein binds copper in vivo. Nature 390, 684-687 (1997).
25. Millhauser GL: Copper and the prion protein: methods, structure, function, and disease. Annu. Rev. Phys. Chem. 58, 299-320 (2007).
26. Zanata SM, Lopes MH, Mercadante AF et al.: Stress-inducible protein 1 is a cell surface ligand for cellular prion that triggers neruoprotection. EMBO J. 21, 3307-3316 (2002).
27. Ellis V, Daniels M, Misra R, Brown DR: Plasminogen activation is stimulated by prion protein and regulated in a copper dependent manner. Biochem. 41, 6891-6896 (2002).
28. Edenhofer F, Rieger R, Famulok M, Wendler W, Weiss S, Winnacker EL: Prion protein PrPc interacts with chaperones of the Hsp60 family. J. Virol. 70, 4724-4728 (1996).
29. Keshet GI, Bar-Peled O, Yaffe D, Nudel U, Gabizon R: The cellular prion protein colocalizes with the dystroglycan complexes in the brain. J. Neurochem. 75, 1889-1897 (2000).
30. Mani K, Cheng F, Havsmark B, Jönsson M, Belting M, Fransson LA: Prion, amyloid-b-derived Cu(II) ions, or free Zn(II) ions support S-nitroso-dependent autocleavage of glypican-1 heparan sulfate. J. Biol. Chem. 278(40), 38956-38965 (2003).
31. Lysek DA, Wuthrich K: Prion protein interaction with the C-terminal SH3 domain of Grb2 studied using NMR and optical spectroscopy. Biochem. 43, 10393-10399 (2004).
32. Nieznanski K, Nieznanska H, Skowronek KJ, Osiecka KM, Stepkowski D: Direct interaction between prion protein and tubulin. Biochem. Biphys. Res. Commun. 334, 403-411 (2005).
33. Klein TR, Kirsch D, Kaufmann R, Riesner D: Prion rods contain small amounts of two host sphingolipids as revealed by thin-layer chromatography and mass spectrometry. Biol. Chem. 379(6), 655-666 (1998).
34. Nandi PK: Interaction of HuPrP106-126 with nucleic acid. Arch. Virol. 142, 2537-2545 (1997).
35. Mouillet-Richard S, Ermonval M, Chebassier C et al.: Signal transduction through prion. Science 289, 1925-1928 (2000).
36. Lingwood D, Simons K: Lipid rafts as a membrane-organizing principle. Science 327, 46-50 (2010).
37. Parat MO: The biology of caveolae: achievements and perspectives. Int. Rev. Cell Mol. Biol. 273, 117-162 (2009).
38. Harmey JH, Doyle D, Brown V, Rogers MS: The cellular isoform of the prion protein, PrPC is associated with caveolae in mouse neuroblastoma (N2a) cells. Biochem. Biophy. Res. Comm. 25, 753-759 (1995).
39. Toni M, Spisni E, Griffoni C et al.: Cellular prion protein and caveolin-1 interaction in a neuronal cell line precedes fyn/erk1/2 signal transduction. J. Biomed. Biotechnol. 5, 69469 (2006).
40. Okamoto T, Schlegel A, Scherer PE, Lisanti MP: Caveolins, a family of scaffolding proteins for organizing "preassembled signaling complexes" at the plasma membrane. J. Biol. Chem. 273, 5419-5422 (1998).
41. Paitel E, Fahraeus R, Checler F: Cellular prion protein sensitizes neurons to apoptotic stimuli through Mdm2-regulated and p53-dependent caspase 3-like activation. J. Biol. Chem. 278(12), 10061-10066 (2003).
42. Kuwahara C, Takeuchi AM, Nishimura T et al.: Prions prevent neuronal cell line death. Nature 400, 225-226 (1999).
43. Chiarini LB, Freitas AR, Zanata SM, Brentani RR, Martins VR, Linden R: PrPC transduces neuroprotective signals. EMBO J. 21, 317-326 (2002).
44. Bounhar Y, Zhang Y, Goodyer CG, LeBlanc A: Prion protein protects human neurons against Bax-mediated apoptosis. J. Biol. Chem. 276, 39145-39149 (2001).
45. Choi CJ, Anantharam V, Saetveit NJ, Houk RS, Kanthasamy A, Kanthasamy AG: Normal cellular prion protein protects against manganese-induced oxidative stress and apoptotic cell dead. Toxicol. Sci. 98, 495-509 (2007).
46. Diarra-Mehrpour M, Arrabal S, Jalil A et al.: Prion protein prevents human breast carcinoma cell line from tumor necrosis factor-induced cell death. Cancer Res. 64, 719-727 (2004).
47. Anantharam V, Kanthasamy A, Choi CJ et al.: Opposing role of prion protein in oxidative stress- and ER stress-induced apoptotic signaling. Free Radic. Biol. Med. 45(11), 1530-1541 (2008).
48. Laurén J, Gimbel DA, Nygaard HB et al.: Cellular prion protein mediates impairment of synaptic plasticity by amyloid-b oligomers. Nature 457, 1128-1132 (2009).
49. Steele AD, Zhou Z, Jackson WS et al.: Context dependent neuroprotective properties of prion protein (PrP). Prion 3, 240-249 (2009).
50. Hay B, Barry RA, Lieberburg I, Prusiner SB, Lingappa VR: Biogenesis and transmembrane orientation of the cellular isoform of the scrapie prion protein. Mol. Cell Biol. 7, 914-920 (1987).
51. Hegde RS, Mastrianni JA, Scott MR et al.: A transmembrane form of the prion protein in neurodegenerative disease. Science 279, 827-834 (1998).
52. Vincent B, Paitel E, Saftig P et al.: The disintegrins ADAM10 and TACE contribute to the constitutive and phorbol ester-regulated normal cleavage of the normal cellular prion protein. J. Bio. Chem. 276, 37743-37746 (2001).
53. Brown P: Creutzfledt-Jakob disease: reflections on the risk from blood product therapy. Haemophilia 13, 33-40 (2007).
54. Franscini N, El Gedaily A, Matthey U et al.: Prion protein in milk. PLoS ONE 1, e71 (2006).
55. Shaked GM, Shaked Y, Kariv-Inbal Z, Halimi M, Avraham I, Gabizon R: A protease-resistant prion protein isoform is present in urine of animals and human affected with prion diseases. J. Biol. Chem. 276(34), 31479-31482 (2001).
56. Büeler H, Fischer M, Lang Y et al.: Normal development and behavior of mice lacking the neuronal cell-surface PrP protein. Nature 356, 577-582 (1992).
57. Maeda Y, Ashida H, Kinoshita T: CHO glycosylation mutants: GPI anchor. Methods Enzymol. 416, 182-205 (2006).
58. Ikezawa H: GPI-anchored proteins. Biol. Pharm. Bull. 25, 409-417 (2002).
59. Orlean P, Menon AK: Thematic review series: lipid posttranslational modifications. GPI anchoring of protein in yeast and mammalian cells, or: how we learned to stop worrying and love glycophospholipids. J. Lipid Res. 48, 993-1011 (2007).
60. Waneck GL, Stein ME, Flavell RA et al.: Conversion of a GPI-anchored protein to an integral membrane protein by a single amino acid mutation. Science 241, 697-699 (1998).
61. Chen R, Knez JJ, Merrick WC, Medof ME: Comparative efficiencies of C-terminal signals of native GP-anchored proproteins in conferring GPI-anchoring. J. Cell Biochem. 84, 68-83 (2001).
62. Screaton RA, DeMarte L, Dráber P, Stanners CP: The specificity for the differentiation blocking activity of carcinoembryonic antigen resides in its GPI anchor. J. Cell Biol. 150, 613-626 (2000).
63. Nicholson TB, Stanners CP: Identification of a novel functional specificity signal within the GPI anchor signal sequence of carcinoembryonic antigen. J. Cell Biol. 177, 211-218 (2007).
64. Naghibalhossaini F, Yoder AD, Tobi M, Stanners CP: Evolution of a tumorigenic property conferred by glycophosphatidyl-inositol membrane anchors of carcinoembryonic antigen gene family members during the primate radiation. Mol. Biol. Cell. 18, 1366-1374 (2007).
65. Wopfner F, Weidenhöfer G, Schneider R et al.: Analysis of 27 mammalian and 9 avaian PrPs reveal high conservation of flexible regions of the prion protein. J. Mol. Biol. 289, 1163-1178 (1999).
66. Guo Z, Linn JF, Wu G et al.: CDC91L1(PIG-U) is a newly discovered oncogene in human bladder cancer. Nat. Med. 10, 374-381 (2004).
67. Jiang WW, Zahurak M, Zhou ZT et al.: Alteration of GPI transamidase subunits in head and neck squamous carcinoma. Mol. Cancer 6, 74-80 (2008).
68. Wu G, Guo Z, Chatterjee A et al.: Over expression of GPI transamidase subunits GPI glycan class T and/or GPI anchor attachment 1 induces tumorigenesis and contributes to invasion in human breast cancer. Cancer Res. 66, 9829-9836 (2006).
69. Ho JC, Cheung ST, Patil M, Chen X, Fan ST: Increased expression of GPI-anchor attachment protein 1 (GPAA1) is associated with gene amplification in hepatocellular carcinoma. Int. J. Cancer 119, 1330-1337 (2006).
70. Malumbres M, Barbacid M: Ras oncogenes: the first 30 years. Nat. Rev. Cancer 3, 459-460 (2003).
71. Wennerberg K, Rossman KL, Der CJ: The Ras super-family at a glance. J. Cell Sci. 118, 843-846 (2005).
72. Sobering AK, Watanabe R, Romeo MJ et al.: Yeast Ras regulates the complex that catalyzes the first step in GPI-anchor biosynthesis at the ER. Cell 117, 637-648 (2004).
73. Holzmann K, Kohlhammer H, Schwaenen C et al.: Genomic DNA-chip hybridization reveals a higher incidence of genomic amplification in pancreatic cancer than conventional comparative genomic hybridization leads to identification of novel candidate genes. Cancer Res. 64, 4428-4433 (2004).
74. Nowak NJ, Gaile D, Conroy JM et al.: Genome-wide aberrations in pancreatic adenocarcinoma. Cancer Genet. Cytogenet. 161, 36-50 (2005).
75. Aguirre AJ, Brennan C, Bailey G et al.: High-resolution characterization of the pancreatic adenocarcinoma genome. Proc. Nat. Acad. Sci. U.S.A. 101, 9067-9072 (2004).
76. Liang J, Pan YL, Ning XX et al.: Overexpression of PrPC and its antiapoptosis function in gastric cancer. Tumor Biol. 27, 84-91 (2006).
77. Antonacopoulou AG, Grivas PD, Skarlas L et al.: POLR2F, ATP6V0A1 and PRNP expression in colorectal cancer: new molecules with prognostic significance? Anticancer Res. 28, 1221-1227 (2008).
78. Han H, Bearss DJ, Browne LW, Calaluce R, Nagle RB, Von Hoff DD: Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res. 62, 2890-2896 (2002).
79. Maitra A, Hruban RH: Pancreatic cancer. Ann. Rev. Pathol. 3, 157-188 (2008).
80. Jemal A, Murray T, Ward E et al.: Cancer Statistics, 2005. CA Cancer J. Clin. 55, 10-30 (2005).
81. Warshaw AL, Fernández-del Castillo C: Pancreatic carcinoma. N. Engl. J. Med. 326, 455-465 (1992).
82. Hruban RH, Adsay NV, Albores-Saavedra J et al.: Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am. J. Surg. Pathol. 25, 579-586 (2001).
83. Hruban RH, Wilentz RE, Maitra A: Identification and analysis of precursors to invasive pancreatic cancer. Methods Mol. Med. 103, 1-13 (2005).
84. Yamano M, Fujii H, Takagaki T, Kadowaki N, Watanabe H, Shirai T: Genetic progression and divergence in pancreatic carcinoma. Am. J. Pathol. 156, 2123-2133 (2000).
85. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA: Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 20, 1218-1249 (2006).
86. Rustgi AK: The molecular pathogenesis of pancreatic cancer: clarifying a complex circuitry. Genes Dev. 20, 3049-3053 (2006).
87. Li C, Yu S, Nakamura F et al.: Binding of pro-prion to filamin A disrupts cytoskeleton and correlates with poor prognosis in pancreatic cancer. J. Clin. Invest. 119(9), 2725-2736 (2009).
88. Stossel TP, Condeelis J, Cooley L et al.: Filamins as integrators of cell mechanics and signaling. Nat. Rev. Mol. Cell Biol. 2, 138-145 (2001).
89. Feng Y, Walsh CA: The many faces of filamin: a versatile molecular scaffold for cell motility and signaling. Nat. Cell Biol. 6, 1034-1038 (2004).
90. Robertson SP: Filamin A: phenotypic diversity. Curr. Opin. Genet. Dev. 15, 301-307 (2005).
91. Hart AW, Morgan JE, Schneider J et al.: Cardiac malformations and midline skeletal defects in mice lacking filamin A. Hum. Mol. Genet. 15, 2457-2467 (2006).
92. Feng Y, Chen MH, Moskowitz IP et al.: Filamin A is required for cell-cell contact in vascular development and cardiac morphogenesis. Proc. Nat. Acad. Sci. USA 103, 19836-19841 (2006).
93. Kiema T, Lad Y, Jiang P et al.: The molecular basis of filamin binding to integrins and competition with talin. Mol. Cell. 21, 337-347 (2006).
94. Nakamura F, Pudas R, Heikkinen O et al.: The structure of the GPIb-filamin A complex. Blood 107, 1925-1932 (2006).
95. Nakamura F, Osborn TM, Hartemink CA, Hartwig JH, Stossel TP: Structural basis of filamin A functions. J. Cell Biol. 179, 1011-1025 (2007).
96. Cancellotti E, Wiseman F, Tuzi NL et al.: Altered glycosylated PrP proteins can have different neuronal trafficking in brain but do not acquire scrapie-like properties. J. Biol. Chem. 280, 42909-42918 (2005).
97. Devasahayam M, Catalino PD, Rudd PM, Dwek RA, Barclay AN: The glycan processing and site occupancy of recombinant Thy-1 is markedly affected by the presence of a GPI-anchor. Glycobiology 9, 1381-1387 (1999).
98. Bashyam MD, Bair R, Kim YH et al.: Array-based comparative genomic hybridization identifies localized DNA amplifications and homozygous deletions in pancreatic cancer. Neoplasia 7, 556-562 (2005).
99. Guillot-Sestier MV, Sunyach C, Druon C, Scarzello S, Checler F: The a-secretase-derived N-terminal product of cellular prion, N1 displays neuroprotective function, in vitro and in vivo. J. Biol. Chem. 284(51), 35973-35986 (2009).
100. Byers HR, Etoh T, Doherty JR, Sober AJ, Mihm MC Jr: Cell migration and actin organization in cultured human primary, recurrent, cutaneous and metastatic melanoma. Am. J. Pathol. 139, 423-435 (1991).
101. Cunningham CC, Gorlin JB, Kwiatkowski DJ et al.: Actin-binding protein requirement for cortical stability and efficient locomotion. Science 255, 325-327 (1992).
102. Glogauer M, Arora P, Chou D, Janmey PA, Downey GP, McCulloch CAG: The role of actin-binding protein 280 in integrin-dependent mechanoprotection. J. Biol. Chem. 273, 1689-1698 (1998).
103. He H-J, Kole S, Kwon Y-K, Crow MT, Bernier M: Interaction of filamin A with the insulin receptor alters insulin-dependent activation of the mitogen-activated protein kinase pathway. J. Biol. Chem. 278, 27096-27104 (2003).
104. Sasaki A, Masuda Y, Ohta Y, Ikeda K, Watanabe K: Filamin associates with Smads and regulates transforming growth factor beta signaling. J. Biol. Chem. 276, 17871-17877 (2001).
105. Zhang M, Breitwieser GE: High affinity interaction with filamin A protects against calcium-sensing receptor degradation. J. Biol. Chem. 280, 11140-11146 (2005).
106. Pammer J, Weninger W, Tschachler E: Human keratinocytes express cellular prion-related protein in vitro and during inflammatory skin diseases. Am. J. Pathol. 5, 1353-1358 (1998).
107. Bouffard D, Duncan LM, Howard CA, Mihm MC Jr, Byers HR: Actin binding protein expression in benign and malignant melanocytic proliferations. Hum. Pathol. 25, 709-714 (1994).
108. Mínguez B, Tovar V, Chiang D, Villanueva A, Llovet JM: Pathogenesis of hepatocellular carcinoma and molecular therapies. Curr. Opin. Gastroenterol. 25, 186-194 (2009).
109. Jackman DM, Johnson BE: Small-cell lung cancer. Lancet 366, 1385-1396 (2005).
110. Yin S, Fan X, Yu S, Li C, Sy MS: Binding of recombinant but not endogenous prion protein to DNA causes DNA internalization and expression mammalian cells. J. Biol. Chem. 283, 25446-25454 (2008).